Wikia

Psychology Wiki

Changes: Paliperidone

Edit

Back to page

(New page: {{BioPsy}} {{Drugbox| |IUPAC_name = 3-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-7-<br />hydroxy-4-methyl-1,5-diazabicyclo[4.4.0]deca-3,5-dien-2-one | image=Paliperidone.svg ...)
 
 
Line 20: Line 20:
 
| routes_of_administration=oral- extended release
 
| routes_of_administration=oral- extended release
 
}}
 
}}
'''Paliperidone (Sold as INVEGA, Semap)''' is an [[atypical antipsychotic]] developed by [[Janssen Pharmaceutica]]. Invega is an extended release formulation of paliperidone that uses the [[OROS]] extended release system to allow for once-daily dosing. Chemically, paliperidone is primary active metabolite of the older antipsychotic [[risperidone]] (paliperidone is 9-hydroxyrisperidone, i.e. risperidone with an extra [[hydroxyl]] group). While its specific mechanism of action is unknown, it is believed paliperidone and risperidone act via similar, if not the same, pathways.
+
'''Paliperidone (Sold as INVEGA, Semap)''' is an [[atypical antipsychotic]] developed by Janssen Pharmaceutica. Invega is an extended release formulation of paliperidone that uses the OROS (Osmotic Release Oral Systems) extended release system to allow for once-daily dosing. Chemically, paliperidone is primary active metabolite of the older antipsychotic [[risperidone]] (paliperidone is 9-hydroxyrisperidone, i.e. risperidone with an extra [[hydroxyl]] group). While its specific mechanism of action is unknown, it is believed paliperidone and risperidone act via similar, if not the same, pathways.
   
 
Paliperidone (as Invega) was approved by the FDA for treatment of schizophrenia on December 20, 2006. This agent will initially be marketed for the treatment of schizophrenia and then for bipolar mania. Clinical trials of paliperidone for the treatment of schizoaffective disorder are also planned.
 
Paliperidone (as Invega) was approved by the FDA for treatment of schizophrenia on December 20, 2006. This agent will initially be marketed for the treatment of schizophrenia and then for bipolar mania. Clinical trials of paliperidone for the treatment of schizoaffective disorder are also planned.
Line 26: Line 26:
 
==See also==
 
==See also==
 
* [[Risperidone]]
 
* [[Risperidone]]
* [[OROS]]
+
   
 
==External Link==
 
==External Link==

Latest revision as of 22:43, September 13, 2007

Assessment | Biopsychology | Comparative | Cognitive | Developmental | Language | Individual differences | Personality | Philosophy | Social |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |

Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)


Paliperidone chemical structure
Paliperidone

3-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-7-
hydroxy-4-methyl-1,5-diazabicyclo[4.4.0]deca-3,5-dien-2-one
IUPAC name
CAS number
144598-75-4
ATC code

N05AX13

PubChem
115237
DrugBank
[1]
Chemical formula {{{chemical_formula}}}
Molecular weight 426.484 g/mol
Bioavailability 28%
Metabolism
Elimination half-life 23 hours
Excretion
Pregnancy category C
Legal status Rx-only
Routes of administration oral- extended release

Paliperidone (Sold as INVEGA, Semap) is an atypical antipsychotic developed by Janssen Pharmaceutica. Invega is an extended release formulation of paliperidone that uses the OROS (Osmotic Release Oral Systems) extended release system to allow for once-daily dosing. Chemically, paliperidone is primary active metabolite of the older antipsychotic risperidone (paliperidone is 9-hydroxyrisperidone, i.e. risperidone with an extra hydroxyl group). While its specific mechanism of action is unknown, it is believed paliperidone and risperidone act via similar, if not the same, pathways.

Paliperidone (as Invega) was approved by the FDA for treatment of schizophrenia on December 20, 2006. This agent will initially be marketed for the treatment of schizophrenia and then for bipolar mania. Clinical trials of paliperidone for the treatment of schizoaffective disorder are also planned.

See alsoEdit


External LinkEdit

INVEGA Web site


ru:Палиперидон
de:Paliperidon
This page uses Creative Commons Licensed content from Wikipedia (view authors).

Around Wikia's network

Random Wiki